Pharma patent wars: Congress caps litigation harassment against generics

What it does

This bill limits pharmaceutical and biological product makers to asserting only one patent per 'Patent Group' (a cluster of related patents linked by USPTO disclaimers) in any single infringement lawsuit against generic drug applicants or biosimilar makers. It prevents patent holders from filing multiple lawsuits against the same generic/biosimilar competitor using different patents from the same group, reducing litigation harassment and lowering barriers to market entry for cheaper alternatives.

Why we flagged it

The bill directly addresses patent thickets—a well-documented anticompetitive practice in pharmaceutical litigation—by constraining how many related patents a single patent holder can assert in one lawsuit. It is a targeted procedural reform, not a broad deregulation or subsidy.

What the text implies

• Patent holders may respond by filing separate lawsuits against the same generic/biosimilar competitor using different Patent Groups, potentially shifting litigation burden rather than reducing it.
• The definition of 'Patent Group' depends on USPTO disclaimer practices under 35 U.S.C. § 253; changes to disclaimer rules or interpretation could alter the scope of the restriction.
• Applies only to drug and biological product litigation; does not affect patent thicket tactics in other industries (software, hardware, telecommunications).
• May incentivize patent holders to structure patent portfolios differently to avoid disclaimer linkages, creating new strategic behavior.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Generic and biosimilar drugs reach patients faster and at lower cost when patent holders cannot weaponize overlapping patent portfolios to delay market entry through serial litigation. Consumers and public health systems benefit from reduced drug prices and faster generic/biosimilar availability.

Who stands to gain

• generic pharmaceutical manufacturers
• biosimilar manufacturers
• pharmacy benefit managers
• health insurance companies

Named in the bill

35 U.S.C. § 271(e), 35 U.S.C. § 253, Federal Food, Drug, and Cosmetic Act § 505, Public Health Service Act § 351(k), USPTO, generic drug applicants, biosimilar manufacturers

Where it stands

9 cosponsors: 6 Democrats, 3 Republicans.

• May 8, 2025 — Introduced · Congress.gov: “Introduced in House”
• May 8, 2025 — Referred to House Committee on the Judiciary · Congress.gov: “Referred to the House Committee on the Judiciary”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

23 lobbying clients named this bill on 29 disclosure filings across 3 quarters, Dec 2025 to Jun 2026. Those filings disclosed $47,272,577 in lobbying spend. A filing names 23 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 97% of bills with at least one filing.

Jodey Arrington, the sponsor, reported $573,000 in PAC receipts in the 2026 cycle. $2,500 of that came from 1 PAC tied to these lobbying clients.

• Chamber of Commerce of the U.S.A. — $16,950,000 on 1 filing
• Pharmaceutical Research and Manufacturers of America — $15,770,000 on 2 filings
• Amgen Inc — $2,440,000 on 1 filing
• Biotechnology Innovation Organization — $2,360,000 on 1 filing
• Bayer Corporation (consolidated Report) — $1,820,000 on 1 filing

Lobbying Disclosure Act filings through Jul 22, 2026. A filing shows who paid to lobby on a bill it names, not what changed.